Final design and implementation plan for evaluating the effectiveness of FMVSS 213: child seating systems.

National Highway Traffic Safety Administration, Washington, D.C.

Final design and implementation plan for evaluating the effectiveness of FMVSS 105: hydraulic brake systems in passenger cars.

National Highway Traffic Safety Administration, Washington, D.C.

Final design and implementation plan for evaluating the effectiveness of FMVSS 202: head restraints, and FMVSS 207: seating systems.

National Highway Traffic Safety Administration, Washington, D.C.

Final design and implementation plan for evaluating the effectiveness of FMVSS 220--school bus rollover protection, FMVSS 221--school bus body joint strength, FMVSS 222--school bus seating and crash protection.

National Highway Traffic Safety Administration, Washington, D.C.

Effectiveness of alternative skid reduction measures - volume III: users manual. Final report.

Federal Highway Administration, Office of Research and Development, Washington, D.C.

Effectiveness of alternative skid reduction measures - volume IV: criteria for improvement of pavement surface macrotexture. Final report.

Federal Highway Administration, Office of Research and Development, Washington, D.C.

Special Adjudication for Enforcement (SAFE) - volume I.

National Highway Traffic Safety Administration, Washington, D.C.

Cost of clean water.

v. 1. Municipal investment needs.--v. 2. Cost effectiveness and clean water.

Cost evaluation for four federal motor vehicle safety standards. Volume II: appendices. Final report.

National Highway Traffic Safety Administration, Washington, D.C.

Cost/benefit study of National Shipbuilding Research Program. 1971 to present.

Mode of access: Internet.

Value Assessment of Orphan Drugs and Treatments for Rare Diseases

Thesis (Master's)--University of Washington, 2016-06

Identifying and overcoming barriers to raising funds from individuals for tobacco prevention

Thesis (Master's)--University of Washington, 2016-06

The burden of major depression avoidable by longer-term treatment strategies

Background: Major depression is the largest single cause of nonfatal disease burden in Australia. Effective drug and psychological treatments exist, yet are underused. Objective: To quantify the burden of disease currently averted in people seeking care for major depression and the amount of disease burden that could be averted in these people under optimal episodic and maintenance treatment strategies. Design: Modeling impact of current and optimal treatment strategies based on secondary analysis of mental health survey data, studies of the natural history of major depression, and meta-analyses of effectiveness data. Monte Carlo simulation of uncertainty in the model. Setting: The cohort of Australian adults experiencing an episode of major depression in 2000 are modeled through "what if" scenarios of no treatment, current treatment, and optimal treatment strategies with cognitive behavioral therapy or antidepressant drug treatment. Main Outcome Measure: Disability-Adjusted Life Year. Results: Current episodic treatment averts 9% (95% uncertainty interval, 6%-12%) of the disease burden of major depression in Australian adults. Optimal episodic treatment with cognitive behavioral therapy could avert 28% (95% uncertainty interval, 19%-39%) of this disease burden, and with drugs 24% (95% uncertainty interval, 19%-30%) could be averted. During the 5 years after an episode of major depression, current episodic treatment patterns would avert 13% (95% uncertainty interval, 10%-17%) of Disability-Adjusted Life Years, whereas maintenance drug treatment could avert 50% (95% uncertainty interval, 40%-60%) and maintenance cognitive behavioral therapy could avert 52% (95% uncertainty interval, 42%-64%), even if adherence of around 60% is taken into account. Conclusions: Longer-term maintenance drug or psychological treatment strategies are required to make significant inroads into the large disease burden associated with major depression in the Australian population.